Novartis and the University of Pennsylvania have issued a clinical update of their cell therapy for paediatric patients with acute lymphoblastic leukaemia (ALL) showing that 36 out of 39 patients, or 92% of trial participants, experienced a complete remission of their disease.
Content matching 'novartis'
ISCT revises cell and gene therapy forecast following FDA approval of Novartis CAR-T therapy
Why the FDA’s CAR-T approval sends strong signal to cell therapy industry: an interview with Martin Lamb
Spotlight on immunotherapy, Spotlight on commercialization and translation, Spotlight on cell therapy regulation, Latest news & views, Cell therapy, Industry developments, Manufacturing & scale-up
Cell therapy weekly: Kymriah could be available in Japan and stem cells show benefits against multiple sclerosis
Latest developments compiled from 1 July until 31 August 2014
Research by Douglas Melton of Harvard University and colleagues showing that insulin-producing pancreatic beta cells can be created in a laboratory has reached the stage of commercialisation with the launch of a new company aimed at bringing a cell therapy for diabetes into human trials.
The buzz at the Phacilitate Cell & Gene Therapy Forum in Washington DC on 26 to 28 January was that gene therapy will become a mainstream activity in the global pharmaceutical industry over the next five years, driven in part by the new gene-modified cell therapies and genome editing.